New Data on Emerging Treatments for Psoriasis

Slides:

Advertisements

Similar presentations

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

Advertisements

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

New Horizons for SMA.

New Psoriasis Treatments

Evolution of Treatment Strategies Targeting IL-23 for Psoriasis

Unraveling Clinical Developments in NASH

Improving Survival in Glioblastoma Multiforme

T-Cell Exhaustion: Can We Overcome It in Cancer?

Advances in Managing Inhibitors in Patients With Hemophilia A

Relapsed/Refractory Follicular Lymphoma Conundrums

Clinical Developments in Inflammatory Arthritis 2017

Updates on Emerging GLP-1 Receptor Agonists

Progression After Cancer Immunotherapy in Advanced NSCLC

From Conference to Practice: Big Data in Psoriasis

Mid-Year Hemophilia Update

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Addressing Disease Burden in Asthma

The Evolving Role of Immunotherapy in NSCLC

Optimizing Management of Advanced Bladder Cancer

Postpartum Depression

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Hyperhidrosis Is Burdensome!

Therapeutic Approaches to the Management of EDS in OSA

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

Novel Approaches in T1D Management

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

Improving Outcomes in Psoriatic Arthritis

Personalizing Management in the Care of Patients With Advanced Sarcoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Developments in the Wet AMD Treatment Landscape

Parkinson Disease Psychosis

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Ask the Psoriasis Expert

The Burden of Psoriasis:

Patient Questions and Expert Answers in Psoriasis:

The Psychiatrist's Role in Tardive Dyskinesia

Patient and Clinician Perspectives on Preventive Therapy for Migraine

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

EXPERT INSIGHTS: IL-17 INHIBITION IN PSORIASIS CARE

Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Psychiatrist's Role in Tardive Dyskinesia

Peanut Allergy Immunotherapy

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

VKA Reversal and LVADs.

Targeting IL-23 for Therapeutic Longevity in Psoriasis

Understanding How IL-23p19 Inhibitors Work in Psoriasis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Areas of Special Interest in PsO

Psoriatic Arthritis.

Presentation transcript:

New Data on Emerging Treatments for Psoriasis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

PASI 75 is Obsolete

Updates on IL-17 Targeted Therapies

Secukinumab OPTIMISE Phase 3b Study

Ixekizumab Long-Term Safety Data

Brodalumab Across Different Body Regions

IL-17 Blockers Conclusions

The Latest on IL-23 Targeted Treatments

IL-23 Blockers

Guselkumab Patient-Reported Outcomes From VOYAGE-2 Study

Tildrakizumab Patient-Reported Outcomes From reSURFACE 1 and reSURFACE 2

Long-Term Efficacy of Tildrakizumab

IL-23 Blockers Concluding Remarks

Targeted Agents in Development

Risankizumab Patient-Reported Outcomes From UltIMMa Trials

Mirikizumab 52-Week Efficacy Data From Phase 2 Trial

Mirikizumab 16-Week Data From Phase 2 Trial

Bimekizumab Efficacy and QoL From Phase 2 Trial

TYK2 A New Target in Psoriasis

BMS-986165 Efficacy Data From Phase 2 Trial

Investigational Agents Unanswered Questions

Concluding Remarks

Abbreviations

Abbreviations (cont)